Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Hybio Pharmaceutical Licenses Semaglutide to Vitamedic for Brazil Market

Fineline Cube Jan 11, 2026
Company Deals

Merck in Talks to Acquire Revolution Medicines for $28‑32 Billion in Oncology Push

Fineline Cube Jan 11, 2026
Company Deals

Takeda Licenses Halozyme’s ENHANZE Technology for Vedolizumab in Global Deal

Fineline Cube Jan 11, 2026
Company Deals

Eisai China and Xuanwu Hospital Forge Strategic Cooperation for Drug R&D

Fineline Cube Jan 11, 2026
Company Deals

InduPro Partners with Lilly on $950M Oncology Deal Using Proximity-Guided Platform

Fineline Cube Jan 10, 2026
Policy / Regulatory

NMPA Issues New Rules to Strengthen Pharmaceutical Contract Manufacturing Oversight

Fineline Cube Jan 9, 2026
Company Drug

Genrix Bio’s GR1803 NDA Accepted for BCMA-Targeted Multiple Myeloma Therapy

Fineline Cube Jan 11, 2026
Company Drug

RemeGen’s RC48 Wins Fourth Breakthrough Therapy Designation for Gastric Cancer Combo

Fineline Cube Jan 11, 2026
Company Drug

Jiangsu Alpha Biopharma’s Zorifertinib NDA Accepted for Review by CDE

Fineline Cube Jan 30, 2023

China-based Jiangsu Alpha Biopharma Ltd has announced that the New Drug Application (NDA) for its...

Company Drug

Grand Pharma’s Jext Auto-Injector Approved for Import into Greater Bay Area

Fineline Cube Jan 30, 2023

China-based Grand Pharmaceutical Group Limited (HKG: 0512) has announced receiving official approval from the Guangdong...

Company Drug

Abbisko’s ABSK021 Receives FDA Breakthrough Therapy Designation for TGCT

Fineline Cube Jan 30, 2023

Shanghai-based biotech Abbisko Therapeutics Co., Ltd (HKG: 2256) has announced receiving breakthrough therapy designation (BTD)...

Company Drug

CDE Grants Priority Review Status to Kechow’s HL-085 for Melanoma Treatment

Fineline Cube Jan 30, 2023

The Center for Drug Evaluation (CDE) website indicates that Kechow Pharma’s HL-085 is set to...

Company Drug

NMPA Approves Two China-Developed COVID-19 Small-Molecule Therapies

Fineline Cube Jan 29, 2023

The National Medical Products Administration (NMPA) has issued conditional marketing approvals to two novel, China-discovered...

Policy / Regulatory

China’s NHC Issues Guidelines to Improve Pediatric Medication Management

Fineline Cube Jan 29, 2023

The National Health Commission (NHC) has released a notification aimed at refining management measures for...

Policy / Regulatory

China’s Multi-Bureau Plan Aims to Eradicate Cervical Cancer by 2030

Fineline Cube Jan 29, 2023

The National Health Commission (NHC), Ministry of Education, Ministry of Civil Affairs, and six other...

Company Drug

JS InnoPharm’s US Subsidiary Initiates Phase I Trial for AURKA Inhibitor VIC-1911

Fineline Cube Jan 29, 2023

Shanghai-based JS InnoPharm Ltd has announced the initiation of a Phase I clinical study by...

Company Deals

Akeso Receives First $300M Installment from Summit for Bispecific Antibody Ivonescimab

Fineline Cube Jan 29, 2023

Akeso Inc. (HKG: 9926) has announced receiving the first installment of USD 300 million as...

Policy / Regulatory

NMPA Proposes Emergency Use Management Measures for Medical Devices

Fineline Cube Jan 29, 2023

The National Medical Products Administration (NMPA) has released the “Medical Device Emergency Use Management Measures”...

Company Drug

InnoCare’s Gunagratinib Shows Promising Data in Cholangiocarcinoma at ASCO-GI 2023

Fineline Cube Jan 29, 2023

Beijing InnoCare Pharma Tech Co. (HKG: 9969), a China-based biotech specializing in cancer and autoimmune...

Company Drug

Exegenesis Bio Gains FDA Approval for Gene Therapy EXG102-031 in Wet AMD

Fineline Cube Jan 29, 2023

Hangzhou-based clinical stage gene therapy firm Exegenesis Bio has announced receiving approval from the US...

Company Drug

Simcere’s Cosela Receives First Prescription in China for CDK4/6 Inhibition

Fineline Cube Jan 29, 2023

China-based Simcere Pharmaceutical Group (HKG: 2096) has announced the issuance of the first prescription for...

Policy / Regulatory

China Updates Export Controls on Technologies, Adds Gene Editing to List

Fineline Cube Jan 29, 2023

The Ministry of Finance (MOF) has released an updated notification regarding technologies banned and restricted...

Company Drug

Novartis’ Kisqali Receives NMPA Approval for Premenopausal Breast Cancer

Fineline Cube Jan 28, 2023

Swiss pharmaceutical giant Novartis (NYSE: NVS) has announced receiving marketing approval from the National Medical...

Company Drug

Fosun Pharma’s Comirnaty Bivalent Vaccine Approved in Macau for Booster Shots

Fineline Cube Jan 28, 2023

Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) has announced that its Comirnaty...

Company Drug

HuidaGene Receives FDA IND Approval for Ophthalmology Gene Therapy HG004

Fineline Cube Jan 28, 2023

China-based HuidaGene (Shanghai) Biotechnology Co., Ltd has announced receiving Investigational New Drug (IND) approval from...

Company Deals

Yinghe Brain Science Raises RMB 100 Million in Angel Financing Round

Fineline Cube Jan 28, 2023

Shenzhen Yinghe Brain Science Co., Ltd, a China-based neurotechnology firm, has reportedly raised over RMB...

Company Deals

HutchMed Signs Licensing Deal with Takeda for Global Fruquintinib Development

Fineline Cube Jan 28, 2023

Hutchison China Meditech (HutchMed; HKG: 0013, NASDAQ: HCM) has announced a licensing deal with Japanese...

Company Deals

Tianjin-Based Protein T Raises RMB 100 Million in Series A Financing

Fineline Cube Jan 28, 2023

Tianjin-based biotech Protein T, focused on multi-omics research, has reportedly raised close to RMB 100...

Posts pagination

1 … 510 511 512 … 606

Recent updates

  • Hybio Pharmaceutical Licenses Semaglutide to Vitamedic for Brazil Market
  • Merck in Talks to Acquire Revolution Medicines for $28‑32 Billion in Oncology Push
  • Genrix Bio’s GR1803 NDA Accepted for BCMA-Targeted Multiple Myeloma Therapy
  • RemeGen’s RC48 Wins Fourth Breakthrough Therapy Designation for Gastric Cancer Combo
  • Merck Initiates Phase 3 Trial for Calderasib + KEYTRUDA QLEX in KRAS G12C NSCLC
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Hybio Pharmaceutical Licenses Semaglutide to Vitamedic for Brazil Market

Company Deals

Merck in Talks to Acquire Revolution Medicines for $28‑32 Billion in Oncology Push

Company Drug

Genrix Bio’s GR1803 NDA Accepted for BCMA-Targeted Multiple Myeloma Therapy

Company Drug

RemeGen’s RC48 Wins Fourth Breakthrough Therapy Designation for Gastric Cancer Combo

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.